Abstract:Chemical biology is a scientific interdiscipline spanning the fields of chemistry and biology that involves the application of chemical tools, often compounds, to the study and manipulation of biological systems. Remarkable achievements have been obtained on chemical biology which aims to study important biological events by using small molecular active compounds as a probe thus small active compound has become effective tools in the research of biomedicine. Our research group has achieved a series of results in the molecular mechanism study of leukemic cell differentiation and apoptosis through using small molecular active compounds. We discovered that adenanthin, a diterpenoid compound extracted from Rabdosia adenantha, induces APL-like cell differentiation, represses tumor growth in vivo and prolongs the survival of mouse APL models that are sensitive and resistant to retinoic acid. The chemical probe biotin-tagged adenanthin was designed on the basis of structure-activity relationship data. Further study demonstrated adenanthin directly targets the conserved resolving cysteines of PrxI and Prx II and inhibits their peroxidase activities. Consequently, cellular H 2O 2 is elevated, leading to the activation of extracellular signal regulated kinases and increased transcription of C/EBPβ, which contributes to adenanthin-induced differentiation. In another study we identified a novel natural ent-kaurene diterpenoid derived from I. pharicus leaves called pharicin B that can rapidly stabilize RARα as well as PML-RARα protein and enhances ATRA-dependent transcriptional activity of RARα. Additionally, pharicin B enhances differentiation-enhancing effect of ATRA in AML cell lines, some primary leukemic cells and overcomes retinoid resistance in ATRA-resistant subclones. The effectiveness of the ATRA/pharicin B combination warrants further investigation on their use as a therapeutic strategy for AML patients.Based on our previous study that NSC606985, a novel camptothecin analog, could effectively induce apoptosis in AML cells in a time- and concentration-dependent manner, sequentially through proteolytic activation of protein kinase Cδ (PKCδ), loss of mitochondrial Δωm and caspase-3 activation, we further employed NSC606985 as a molecule probe and systemically investigated the mechanisms of apoptotic induction in AML cells and the prospects of its clinical application in vitro and in vivo. We analyzed protein expression profiles of NSC606985-induced apoptotic AML cells by systematically using phosphoproteomics, quantitive proteomics as well as subcellular proteomics analytical strategy. As a result, we uncovered a series of deregulated proteins including translocated ones during apoptosis, most of which had not been reported previously. Among these apoptotic proteins we identified, the function of ANP32B as well as NDRG1 and their relationship with NSC606985-triggered AML cell apoptosis were further investigated respectively. Moreover, the in vivo study demonstrated that NSC606985 rapidly induced apoptosis of leukemic cells in peripheral blood, bone marrow, liver and spleen, and administration of NSC606985 significantly prolonged the survival of AML mice. The above results provide new leading compound for the acute leukemia therapy. The study of "New Mechanism for Differentiation and Apoptosis of Leukemic cell" wins the National Awards of Natural Sciences (Second prize) in 2010.

Supplementary Materials and Methods from Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells Through PKC Activation

Supplementary Figures S1-S12 from Natural Product Vibsanin A Induces Differentiation of Myeloid Leukemia Cells Through PKC Activation

Supplementary Methods from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Materials and Methods 1 from Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Chemical biology study for differentiation and apoptosis of leukemic cell

Supplementary Material and Methods from New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity

Supplementary Materials and Methods from SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin–Rho GTPase–Hippo Pathways

A Novel Mesenchymal Stem Cell-Based Regimen for Acute Myeloid Leukemia Differentiation Therapy

Supplementary Materials and Methods from Functional Role of a Novel Long Noncoding RNA &Lt;i>ttn-As1</i> in Esophageal Squamous Cell Carcinoma Progression and Metastasis

Natural Products-Based Chemical Biology Research on Leukemic Cell Differentiation

Supplementary Materials SM1 from Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, is Highly Active Against Triple-Negative Breast Cancer